12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

Simcere, Bristol-Myers deal

Bristol-Myers granted Simcere exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers retains rights elsewhere to the small molecule ...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >